Table 4. . Response rate and 6-month progression-free survival in pooled analyses of trials for recurrent GB.
Publication | Sample size | Response rate (%) | PFS6 (%) | OS (months) | 1-year survival (%) | Ref. |
---|---|---|---|---|---|---|
8 MD Anderson trials 1986–1995 | 225 | 6 | 15 | 5.7 | 21 | [23] |
16 NCCTG trials | 345 | N/A | 9 | 5.1 | 14 | [24] |
12 NABTC trials | 437 | 7 | 16 | 6.9 | 25 | [25] |
N/A: Not applicable, NABTC: North American Brain Tumor Coalition; NCCTG: North Central Cancer Treatment Group; OS: Overall survival; PFS6: 6-month progression-free survival.